Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial - Wikidata - awgldk - TriplyDB

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

http://www.wikidata.org/entity/Q30053056

about

Alemtuzumab for multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Optimizing treatment success in multiple sclerosis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Disease-modifying treatments for multiple sclerosis - a review of approved medications Newer therapies for multiple sclerosis Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond B Cells and Autoantibodies in Multiple Sclerosis Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Multiple sclerosis-a quiet revolution Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use New and emerging immune-targeted drugs for the treatment of multiple sclerosis Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis Promoting remyelination in multiple sclerosis-recent advances Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial.Prospects for therapeutic tolerance in humans.Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis Alemtuzumab for Multiple Sclerosis.Multiple sclerosis--new treatment modalities Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations Alemtuzumab for the treatment of multiple sclerosis Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine Therapeutic decisions in multiple sclerosis: moving beyond efficacy Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.First use of alemtuzumab in Balo's concentric sclerosis: a case report.

P2860

Q24185899-2E7BD919-4CE3-4A23-9D66-446772E54FBB Q24187126-AD5E5BEC-A67D-401B-848F-6842788C62C1 Q26752859-FF962FEA-2805-42C6-9B83-EDD52A3B297A Q26765172-D63E5723-9106-44D6-ACDA-C097E39E062F Q26769966-CF43859A-F078-4A9E-831C-AC7B91B6961B Q26770664-EDC3255B-48DB-447E-901B-372385594839 Q26771968-8135ABBF-C8DF-40FB-BCBA-3883FE4904FF Q26776234-E85E19A4-0013-4986-A98C-FDBD6C25E91C Q26777329-7CD8DF4F-E6DD-485B-834A-74E01EFD6B68 Q26779900-3CFAC512-5906-4695-80AF-8F19443E6D46 Q26780412-3DE358DD-A140-4364-B817-6A0CA2EEC929 Q26783585-55B39937-9F15-4817-87D7-F8C4BFE7BBAE Q26798434-97A318A9-CB7D-469E-894C-831DA3FDAB19 Q26800128-316FA5C0-3C62-4FBC-9A86-1E5278D01D7A Q26801386-C4B69201-71D5-4F2E-954F-AE393FA1CEDB Q26822611-FF4F597B-5DF9-4772-9B2F-0BC60A7FACC2 Q26826930-4ABE6E40-472D-4EB6-8D1E-A8CBC29EB406 Q26828463-35A1533F-D830-4990-9789-698FE8C2AB32 Q26849781-2B03D6D7-E3C5-462A-962A-68F78512207B Q26997067-44F4CF57-15D4-49AF-B06A-8828BC09C68F Q27000269-D7DD82CE-1AE2-431E-A149-57E857C29040 Q27009769-9D384943-301A-4037-AD3E-16FB472BCD05 Q27010175-6609F796-4C93-4E51-893E-30CA4ED3C657 Q27010398-C282A9A6-9082-4628-9F2D-354A6CBFF78D Q27307622-2728F29D-9433-4A2F-80D4-898CD589BB18 Q27318199-E9AF7E5E-85FC-4F32-8C09-71554FAE4525 Q27693249-E628555E-7C3B-4D1B-8B37-2FAFCA25EFF6 Q28066677-FEF82F1A-1018-4447-B29A-35DBE1D4CFA8 Q28069730-23E009F0-80BA-4A68-AE58-CD5797FA5D86 Q28072906-9E27C9DC-6E15-4E54-AFBB-6C2BB066A6F7 Q28077000-313FDD83-A144-4E80-ACF6-F3C3BE483CBD Q28080506-13406D60-C94D-45F8-932B-1AE6CE37167B Q28081636-1072301B-9EB1-40BE-8241-C8CCFBF087D9 Q28087414-6931D7FC-44F5-499A-9E6A-BBD94BCEA59B Q28268596-DDC551C8-DCC2-497E-9B12-29FAD90E7EA3 Q28541039-0A21673C-8FCD-4F70-BD60-9BDBA5BD2C01 Q30354658-2C2A5BFF-BB8D-4D80-BEDA-C40A96069136 Q30458930-B94C5A90-D67D-4B82-8858-CBE4D0D690A0 Q30490389-E9E58A14-C972-4156-ACDE-05A1DB011F98 Q30657346-14A78EEB-1D6E-492C-98AF-D16BD8369095

P2860

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

http://www.wikidata.org/entity/Q30053056

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@ast

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@en

type

label

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@ast

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@en

prefLabel

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@ast

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@en

P1433

Q30053056-552FCD85-36B9-4E66-837F-12D6C5F8CF1B

P1476

Q30053056-A721867C-B331-4482-8569-FDC1A966965D

P2093

Q30053056-01626E48-48A4-444C-A2EA-E5645C905978

Q30053056-0E325A26-E899-4C1E-A85A-335A15C04B4E

Q30053056-1D640093-D079-492C-BA95-6759FF773402

Q30053056-1FF746E9-CB7C-4DDA-B0D1-416CA4961ABB

Q30053056-23CE01C7-1BD6-4F9E-9771-67030A355F31

Q30053056-4103929A-343A-4561-82E4-F84A9A3B6F42

Q30053056-51170EA0-44A5-4D85-84A3-BFCB7DB3C0AC

Q30053056-6E7E251C-3DBF-4965-B24E-05DB6A13A9B4

Q30053056-6E92F498-D7A7-45E4-87A5-DED6E5BC0F2A

Q30053056-8E078D96-FDBC-433D-90B4-27988B66BFDF

P304

Q30053056-E4A1E1F3-E537-42D3-B56F-CFF74B89FC10

P31

Q30053056-FE733530-324B-4746-BB25-0BC76EF237BD

P3181

Q30053056-50A5A39A-E104-43D5-8D0E-E58DB8400852

P356

Q30053056-2D9D4500-CF97-4069-A224-32109DECBB37

P407

Q30053056-B1B3A1CD-521C-4535-8F2F-B1025D66DBDC

P433

Q30053056-B1A4C884-0365-48C6-8294-2B330124A2A4

P478

Q30053056-1A1EDBB1-6D8C-4669-8368-0F0018083174

P50

Q30053056-180300AD-B0E5-47E5-AF70-12A36E821274

Q30053056-564EB3F4-F0D2-492E-ACE0-E1376D67C108

Q30053056-AD0AE652-A355-4625-AD80-2AB4AC0FD3EC

P577

Q30053056-52807311-28E8-451B-95E8-6AE94BFF1F93

P698

Q30053056-20749387-07F8-42BE-B80F-0E9A7864601E

P921

Q30053056-5400EB14-6678-4B40-B6FC-33FA62F51013

Q30053056-A89C71CF-14F8-4FE4-9FB3-7E8454E98711

Q30053056-D0CDD4E0-8B09-4B63-87FC-6836F442A68A

P3181

P356

S0140-6736(12)61769-3

P1433

P1476

Alemtuzumab versus interferon ...... mised controlled phase 3 trial

@en

P2093

Alasdair J Coles

http://www.w3.org/2001/XMLSchema#string

Bella I Ertik

http://www.w3.org/2001/XMLSchema#string

Christian Confavreux

http://www.w3.org/2001/XMLSchema#string

D Alastair S Compston

http://www.w3.org/2001/XMLSchema#string

David H Margolin

http://www.w3.org/2001/XMLSchema#string

Douglas L Arnold

http://www.w3.org/2001/XMLSchema#string

Edward J Fox

http://www.w3.org/2001/XMLSchema#string

Elizabeth Fisher

http://www.w3.org/2001/XMLSchema#string

Eva Havrdova

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Cohen

http://www.w3.org/2001/XMLSchema#string

P304

1819-1828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

52824

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(12)61769-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

9856

http://www.w3.org/2001/XMLSchema#string

P478

380

http://www.w3.org/2001/XMLSchema#string

P50

Howard L. Weiner

Hans-Peter Hartung

Gavin Giovannoni

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23122652

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

phase III clinical trial

multiple sclerosis